drugset / Trial / NCT04461925
Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic P_MMSCs and UC-MMSCs
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Assessment of the clinical effects of infusions of cryopreserved allogeneic multipotent mesenchymal stem cells of the placenta and umbilical cord for COVID-19 patients with acute respiratory distress syndrome.
Timeline
- Start
- 2020-05-02
- Primary completion
- 2021-05-02
- Completion
- 2021-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Anticoagulant Therapy | Unknown | — | Subcutaneous |
| Background | Azithromycin | Small molecule | — | Oral |
| Background | Ceftriaxone | Other / unclassified | — | Oral |
| Background | Dexamethasone | Small molecule | — | Intravenous |